

# **Mycenax Biotech Inc.**

## **Board of Directors' Expertise and Diversity**

### **1. Board of Directors Diversity Policy**

On March 10, 2022, Mycenax's Board of Directors revised the "Corporate Governance Best Practice Principles." Chapter three, "Enhancing Board Functions," states that diversity should be considered when forming Board members, and the Directors concurrently serving as company officers shall not exceed one-third of the Board. An appropriate policy on diversity based on Mycenax's business operations and development must be formulated and include, without being limited to, the following two guidelines:

- **Basic requirements**

Gender (At least one seat for female.), age, nationality, and culture, etc.

- **Professional knowledge and skills**

Board members should generally possess the knowledge, skills, and qualities necessary to perform their duties, including a professional background (e.g., law, accounting, industry, finance, marketing or technology), skills and industry experience.

### **2. Implementation**

The current 10th Board of Directors of our company consists of 8 members, including 2 female directors. The Directors possess diverse and complementary skills across various industries, including biotechnology, finance, and law, all with industry experience. Additionally, Mycenax's Directors are multinational, bringing rich experience from different countries and markets. In summary, the members of the Mycenax's Board of Directors have diverse experiences and capabilities, which greatly benefit the overall operations of Mycenax.

Diversity Items			Gender	Nationality	Age	Professional Ability			Industry Experiences	Note
						Biotechnology	Finance /Accounting	Legal Practice		
1	Chairman	Pei-Jiun Chen	Female	R.O.C	51-60	V			V	
2	Director	Chun-Hong Chen	Male	R.O.C	61-70		V		V	
3	Director	Yi-Hsin Lee	Female	R.O.C	41-50		V		V	
4	Director	Jung-Chin Lin	Male	R.O.C	61-70	V	V		V	Note 1
5	Independent Director	Kuo-Pin Kao	Male	R.O.C	61-70		V		V	Note 2
6	Independent Director	Yu-Sheng Tsai	Male	R.O.C	41-50			V	V	
7	Independent Director	Allen Y Chao	Male	USA	71-80	V			V	
8	Independent Director	Kuo-Lung Yen	Male	R.O.C	61-70		V		V	
-	Director	Chia-Ling Lin	Female	R.O.C	31-40	V			V	Note 1
-	Director	Yoh Ito	Male	Japan	61-70	V	V		V	Note 2
-	Director	En-Tzu Liu <sup>1</sup>	Female	R.O.C	31-40		V		V	Note 3

Note 1: Chia-Ling Lin is the representative appointed by Jason Technology Co., Ltd., which resigned from the Board on October 31, 2024. Jason Technology Co., Ltd. appointed Jung-Chin Lin as the new representative on November 1, 2024.

Note 2: Yoh Ito was the representative appointed by JCR Pharmaceuticals Co., Ltd., and JCR Pharmaceuticals Co., Ltd. resigned from the Board on September 27, 2024.

Note 3: En-Tzu Liu is the representative appointed by Nien Hsing International Investment Co., Ltd., which resigned from the Board on April 23, 2024.

**(The information above is based on current 8 seat of directors)**

- ① There are 4 independent directors (an increase from the previous term), accounting for 50%.
- ② The company has 2 female directors, accounting for 25%; and 6 male directors, accounting for 75%.
- ③ The company's board is multinational, with 1 director of U.S. nationality, accounting for 12.5%; the remaining 7 directors are of the same nationality as the company, accounting for 87.5%.
- ④ The age distribution of the company's directors is as follows: 1 director is over 70 years old, accounting for 12.5%; 4 directors are between 61 and 70 years old, accounting for 50%; 1 director is between 51 and 60 years old, accounting for 12.5%; and 2 directors are under 50 years old, accounting for 25%.
- ⑤ There are 3 directors with a professional background in the biotechnology industry, accounting for 37.5%; all 8 directors have industry experience, accounting for 100%.
- ⑥ There are no directors related by marriage or within the second degree of kinship, in compliance with the provisions of Article 26-3, Paragraphs 3 and 4 of the Securities and Exchange Act.